Oncology News | pharmaphorum

News

Swiss hospital adopts Bayer’s AI platform for radiology

A leading Swiss teaching hospital has signed up to use Bayer’s suite of artificial intelligence-powered digital tools for X-ray, MRI, and CT imaging.

News

Pfizer joins three-way PARP battle in prostate cancer

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec

News

FDA delays review of GSK’s momelotinib for myelofibrosis

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all.

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

News

Biomarker for aggressive fibrotic tumours gets FDA backing

A blood test in development that may be able to predict whether a solid tumour will be particularly aggressive has been given the support of the FDA.

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

Swiss hospital adopts Bayer’s AI platform for radiology

Pfizer joins three-way PARP battle in prostate cancer

FDA delays review of GSK’s momelotinib for myelofibrosis

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Biomarker for aggressive fibrotic tumours gets FDA backing

Kura files $100m offer after menin inhibitor results in AML...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks